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ABSTRACT  192 
Liability to alcohol dependence (AD) is heritable, but little is known about its complex 193 
polygenic architecture or its genetic relationship with other disorders. To discover loci 194 
associated with AD and characterize the relationship between AD and other psychiatric 195 
and behavioral outcomes, we carried out the largest GWAS to date of DSM-IV 196 
diagnosed AD. Genome-wide data on 14,904 individuals with AD and 37,944 controls 197 
from 28 case/control and family-based studies were meta-analyzed, stratified by genetic 198 
ancestry (European, N = 46,568; African; N = 6,280). Independent, genome-wide 199 
significant effects of different ADH1B variants were identified in European (rs1229984; p 200 
= 9.8E-13) and African ancestries (rs2066702; p = 2.2E-9). Significant genetic 201 
correlations were observed with 17 phenotypes, including schizophrenia, ADHD, 202 
depression, and use of cigarettes and cannabis. The genetic underpinnings of AD only 203 
partially overlap with those for alcohol consumption, underscoring the genetic distinction 204 
between pathological and non-pathological drinking behaviors. 205 
  206 
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INTRODUCTION 207 
Excessive alcohol use is a leading contributor to morbidity and mortality. One in 20 208 
deaths worldwide is attributable to alcohol consumption, as is 5.1% of the global burden 209 
of disease1. Alcohol dependence (AD), as defined by the Fourth Edition of the American 210 
Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-211 
IV)2, is a serious psychiatric disorder characterized by tolerance, withdrawal, loss of 212 
control over drinking and excessive alcohol consumption despite negative health and 213 
social consequences. Among alcohol drinkers, 12% meet criteria for DSM-IV AD during 214 
their lifetimes3. In the United States, only 25% of those with AD ever receive treatment4.  215 
 216 
AD is moderately heritable (49% by a recent meta-analysis)5 and numerous genome-217 
wide association studies (GWAS) have aimed to identify loci contributing to this genetic 218 
variance (see6 for a review). According to one study, common SNPs are responsible for 219 
as much as 30% of the variance in AD7, but few have been identified to date. Variants in 220 
the genes responsible for alcohol metabolism, especially ADH1B and ALDH2, have 221 
been strongly implicated8–13. The association between AD (and related drinking 222 
phenotypes) and rs1229984, a missense SNP (Arg48His) in ADH1B that affects the 223 
conversion of alcohol to acetaldehyde, represents one of the largest common-variant 224 
effect sizes observed in psychiatry, with the His48 allele accelerating ethanol 225 
metabolism and affording approximately 3-fold reduction in likelihood of AD across 226 
numerous studies8,10. Another functional polymorphism, rs671 in ALDH2 (Glu504Lys), 227 
strongly affects alcohol metabolism by blocking conversion of acetaldehyde to acetate 228 
and has an even stronger effect on risk for AD, but is rare except in some Asian 229 
populations8,12,13 ADH1B and ALDH2 polymorphisms, however, only explain a small 230 
proportion of the heritable variation in AD in populations of European or African 231 
ancestry. 232 
 233 
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In this study, the Substance Use Disorders working group of the Psychiatric Genomics 234 
Consortium (PGC-SUD14) compiled the largest numbers of carefully diagnosed alcohol 235 
dependent individuals and alcohol-exposed controls to date, from both case-control and 236 
family studies. These included substantial numbers of both European ancestry (EU, N = 237 
46,568, including 38,686 unrelated individuals) and admixed African-American ancestry 238 
(AA, N = 6,280, including 5,799 unrelated individuals) subjects. AD diagnoses were 239 
derived from clinician ratings or semi-structured interviews following DSM-IV2 criteria. 240 
Each study was subjected to stringent quality control (QC) before conducting GWAS 241 
within each population of each study, followed by a genome-wide meta-analysis. We 242 
estimated the SNP-heritability (h2g) of AD and examine the extent to which aggregate 243 
genetic variation in AD is related to traits from 45 other GWAS, including continuous 244 
measures of alcohol consumption. We also examined whether polygenic risk scores 245 
(PRS) derived from these analyses predicted alcohol dependence and related 246 
measures of problem drinking in three independent samples. 247 
 248 
RESULTS 249 
 250 
GWAS meta-analyses: The trans-ancestral discovery meta-analysis of GWAS of AD in 251 
28 cohorts (Table 1; Supplementary Table S1) identified a genome-wide significant 252 
(GWS; p < 5E-8) association in the ADH gene cluster on chromosome 4 (Figure 1; 253 
Table 2). Examining this locus in each population (Figure 2), rs1229984 in ADH1B was 254 
the strongest associated variant from the analysis in EU (z = -7.13, p = 9.8E-13), while 255 
rs2066702, also in ADH1B, was the most significant variant in AA (z = -5.98, p = 2.2E-256 
9). Trans-ancestral modelling reinforced the robust effects of rs1229984 and other 257 
ADH1B SNPs on liability to AD across inverse-variance weighted, random effects, and 258 
Bayesian models (Supplementary Figure S1, Supplementary Table S2). 259 
 260 
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Clumping the ADH locus for linkage disequilibrium (LD; r2 < 0.1 within 500 kb) 261 
suggested multiple independent signals in both populations, with the differing leading 262 
alleles reflecting different LD structures and allele frequencies in each population (Table 263 
2, Supplementary Figure S2). Conditional analyses controlling for rs1229984 and 264 
rs2066702 had limited power, but results showed limited attenuation of effect sizes 265 
between marginal and conditional analyses, consistent with the existence of additional 266 
independent effects in the region (Supplementary Table S3; Supplementary Figure 267 
S3). Suggestive independent signals in the genotyped cohorts included trialleleic variant 268 
rs894368 (marginal z = -4.57, p = 4.9E-6; conditional z = -4.53, p = 5.8E-6) and 269 
insertion rs112346244 (marginal odds ratio = 0.912, SE = .024, z = -3.81, p = 1.4E-4; 270 
conditional odds ratio = 0.883, SE = .025, z = -5.05, p = 4.5E-7; Supplementary Table 271 
S3). Several additional variants that were prioritized in the conditional analysis, while 272 
not significant, were in moderate to strong LD with rs698 (marginal odds ratio = 1.115, 273 
SE = .021, z = 5.19, p = 2.1E-7; conditional odds ratio = 1.084, SE = .021, z = 3.78, p = 274 
1.6E-4), a functional ADH1C variant with a role in AD8,11.  275 
 276 
A single novel SNP on chromosome 3, rs7644567, also reached GWS in the meta-277 
analysis (z = 5.68, p = 1.36E-8; Supplementary Figure S4). Potential biological 278 
associations with rs7644567, including chromatin contacts (Supplementary Figure S5) 279 
and cerebellar expression of RBMS3, are summarized in Supplementary Information 280 
A9. However, rs7644567 did not replicate in two independent AA samples (Yale-Penn2 281 
and COGA AAfGWAS) or the independent FINRISK cohort; all three replication cohorts 282 
estimating effects of the minor allele in the opposite direction of the discovery meta-283 
analysis (Supplementary Table S4). The SNP is also rare in most EU samples (minor 284 
allele frequency [MAF] < 0.01), with the current GWAS results primarily attributable to 285 
AA cohorts, along with FinnTwin and NAG-Fin. The EU cohorts in the discovery meta-286 
analysis show no evidence of association of AD with the SNPs in strongest LD with 287 
rs7644567 in African (rs13098461; z = 0.27, p = 0.79) or Finnish (rs9854300; z = 0.10, p 288 
= 0.92) reference samples (Supplementary Information A9). Based on the clear lack 289 
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of replication there is insufficient evidence to conclude rs7644567 is associated with AD 290 
based on the current results. 291 
 292 
There was limited genome-wide evidence for heterogeneity across all cohorts, within 293 
ancestry, between ancestries, or between study designs within ancestry 294 
(Supplementary Information A8; Supplementary Figures S6-S8). Evidence for 295 
inflation from population stratification or other confounding was also limited in the 296 
discovery meta-analysis (lambda = 0.962; Supplementary Figure S9) and within EU 297 
(lambda = 1.053, LD score regression [LDSR] intercept = 1.018) and AA (lambda = 298 
1.007, LDSR intercept = 0.991-0.997; Supplementary Information A11). Gene-level 299 
association testing with MAGMA15 did not identify any additional significant genes in EU 300 
or AA (Supplementary Table S5, Supplementary Information A12), likely due to lack 301 
of power.  302 
 303 
Heritability and genetic correlations: Liability-scale SNP-heritability of AD was 304 
estimated at h2g = 0.090 (SE = 0.019, z = 4.80, p = 8.02E-7) in the meta-analysis of 305 
unrelated EU samples. Exclusion of the ADH1B locus did not substantially modify this 306 
estimate (h2g = 0.089, SE = 0.0185). Nominally significant polygenic signal for the meta-307 
analysis of unrelated AA individuals was observed based on LDSR with scores 308 
computed from 1000 Genomes African populations (z = 2.12, p = 0.017), but the 309 
quantitative estimate of h2g was unstable depending on the choice of reference panel, 310 
reflecting the challenge of correctly specifying LDSR and robustly modelling LD for the 311 
AA population (Supplementary Information A11).  312 
 313 
Significant genetic correlation with AD in EU was observed for 17 traits after correction 314 
for multiple testing (p < 1.11E-3 for 45 tested traits; Figure 3; Supplementary Table 315 
S6). The largest positive correlations were with ever smoking tobacco (rg = 0.708, SE = 316 
0.134, p = 1.3E-7) and lifetime cannabis use (rg = 0.793, SE = 0.217, p = 2.5E-4), and 317 
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with other psychiatric disorders, especially schizophrenia (rg = 0.357, SE = 0.054, p = 318 
3.2E-11), ADHD (rg = 0.444, SE = 0.097, p = 4.2E-6), and depression (rg = 0.561, SE = 319 
0.085, p = 3.5E-11). Educational attainment (rg = -0.468, SE = 0.066, p = 9.7E-13) and 320 
age at first birth (higher values indicate that participants were older when they had their 321 
first child; rg = -0.626, SE = 0.104, p = 2.0E-9) showed significant inverse genetic 322 
correlation with AD suggesting that liability to AD risk was genetically related to lower 323 
educational attainment and lower age at which the participant had his or her first child.  324 
 325 
Unexpected patterns of genetic correlation were observed when comparisons were 326 
made to other alcohol-related measures, indicating that those measures reflect aspects 327 
of alcohol use that are genetically distinguishable. AD was genetically correlated with 328 
alcohol consumption in a meta-analysis of the Alcohol Genome-wide Association 329 
(AlcGen) and Cohorts for Aging and Research in Genomic Epidemiology Plus 330 
(CHARGE+) consortia16 (rg = 0.695, SE = 0.155, p = 6.9E-6) but only modestly with 331 
alcohol consumption from the recent large UK Biobank analysis17 (rg = 0.371, SE = 332 
0.092, p = 5.2E-5). No significant genetic correlation was observed between AD and a 333 
recent GWAS of the Alcohol Use Disorders Identification Test (AUDIT) in a 23andMe 334 
cohort18 (rg = 0.076, SE = 0.171, p = 0.65), perhaps due to the low levels of drinking and 335 
drinking-related problems in that population18. AD is, however, nominally genetically 336 
correlated with GWAS of delay discounting in the 23andMe sample19 (rg = 0.487, SE = 337 
0.178, p = 6.0E-3). 338 
 339 
Association with ADH1B expression: Based on the strong observed association with 340 
rs1229984 and rs2066702 we examined whether other variants affecting ADH1B 341 
expression (eQTLs) were also associated with AD using GTEx V7 results 342 
(https://www.gtexportal.org/)20. Three variants, rs11939328 (EU p = 0.78, AA p = 0.98, 343 
Trans p = 0.78), rs10516440 (EU p = 3.97E-6, AA p = 1.97E-3, Trans p = 4.72E-8), and 344 
rs7664780 (EU p = 0.87, AA p = 0.083, Trans p = 0.405), were selected after LD-345 
informed clumping and the exclusion of variants in LD (r2>0.1) with the GWS coding 346 
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alleles rs1229984 and rs2066702. Of these, only rs10516440 (AD conditional analyses: 347 
EU p = 1.34E-3, AA p = 0.013, Trans p = 7.44E-5) was a significant multi-tissue eQTL in 348 
random effects analysis for ADH1B (SFE = 319.4, SHet = 27.6, p = 1.4E-76), ADH1A (SFE 349 
= 139.4, SHet = 6.6, p = 6.72E-33), and ADH1C (SFE = 167.3, SHet = 8.9, p = 1.9E-39). 350 
Rs10516440 is a LD proxy (r2 > 0.9) of rs6827898 (Table 2) in populations of European 351 
and African descent. These variants are both located in an intergenic region in 352 
the ADH gene cluster between ADH1C and ADH7. In line with the fact that the 353 
protective coding alleles are associated with increased activity of the enzyme encoded 354 
by ADH1B, the major allele rs10516440*A was associated with increased 355 
ADH1B expression and reduced AD risk. 356 
 357 
Associations with other GWS loci: We examined results for the eight independent 358 
variants associated at GWS levels with alcohol consumption in the UK Biobank17 359 
(Supplementary Table S7). Among the UK Biobank findings, three of the four reported 360 
variants in the ADH region of chromosome 4 (rs145452708 – a proxy for rs1229984 361 
with D’=1, rs29001570 and rs35081954) were associated in the present study with AD 362 
(p ranging from 3.5E-5 – 2.3E-10) with sign concordant effects; the remaining variant 363 
was excluded from our analysis due to MAF < 0.01. The UK Biobank lead variant in 364 
KLB, rs11940694, was nominally associated with AD (p = 0.0097), though this does not 365 
surpass multiple testing correction for the eight GWS alcohol consumption loci. We see 366 
little evidence (p > 0.2) for association of AD with the reported loci at GCKR and 367 
CADM2, which may be due to differences in power for the given effect size or because 368 
these genes exert an influence on liability to consume alcohol but not later problems. 369 
The locus on chromosome 18 showed limited regional association with AD, but the 370 
index variant was not present in our analysis because it no longer appears in the 1000 371 
Genomes Phase 3 reference panel21. 372 
 373 
Polygenic Risk Score (PRS) analyses: PRS based on our meta-analysis of AD were 374 
significantly predictive of AD outcomes in all three tested external cohorts. PRS derived 375 
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from the unrelated EU GWAS predicted up to 0.51% of the variance in past month 376 
alcohol use disorder in ALSPAC (p = 0.0195; Supplementary Figure S10A) and up to 377 
0.3% of problem drinking as indexed by the CAGE screener in GS (p = 7.9E-6; 378 
Supplementary Figure S10B). PRS derived from the unrelated AA GWAS predicted up 379 
to 1.7% of the variance in alcohol dependence in the COGA AAfGWAS cohort (p = 380 
1.92E-7; Supplementary Figure 10C).  381 
 382 
Importantly, PRS derived from the unrelated EU GWAS showed much weaker 383 
prediction (maximum R2 = 0.37%, p = 0.01; Supplementary Figure S10D) in the COGA 384 
AAfGWAS than the ancestrally-matched AA GWAS-based PRS despite the much 385 
smaller discovery sample for AA. In addition, the AD PRS also still yielded significant 386 
variance explained after controlling for other genetic factors. Prediction of CAGE scores 387 
in GS remained significant and showed minimal attenuation (R2 = 0.29%, p = 1.0E-5) 388 
after conditioning on PRS for alcohol consumption derived from UK Biobank results17. In 389 
COGA AAfGWAS, the AA PRS derived from our study continued to predict 1.6% of the 390 
variance in alcohol dependence after inclusion of rs2066702 genotype as a covariate, 391 
indicating independent polygenic effects beyond the lead ADH1B variant 392 
(Supplementary Information A14).  393 
 394 
Power analysis: Power analyses indicated that the current meta-analysis is expected 395 
to have at least 41% power to detect very common variants (MAF ≥ 0.25) with odds 396 
ratios ≥ 1.10 at p < 5E-8 and 63% power for p < 1E-6 (Supplementary Figure S11). 397 
Power at p < 1E-6 is relevant because only 5 loci reach that threshold in the current 398 
meta-analysis. Power is lower for less common variants (MAF ≤ 0.05) even with odds 399 
ratios ≥ 1.20 at p < 1E-6 (60% power) and p < 5E-8 (38% power).  400 
 401 
For perspective, power computations using the observed distribution of top effects for 402 
other large GWAS of polygenic traits suggest that we observe significantly fewer 403 
genome-wide significant loci for AD than would be expected if the loci had true effect 404 
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sizes and allele frequencies similar to schizophrenia (expected: 25.4 loci, 95% CI 21-30) 405 
or obesity (expected: 8.9 loci, 95% CI 6-12), but not fewer than would be expected for 406 
effect sizes similar to major depression (Supplementary Information A10, 407 
Supplementary Table S8). 408 
 409 
DISCUSSION 410 
 411 
To our knowledge, this is the largest GWAS of rigorously-defined AD, comprising 412 
14,904 AD individuals and 37,944 controls. We identified known loci in ADH1B that 413 
differed between EU and AA, as well as novel genetic correlations between AD and 414 
psychiatric disorders (e.g., schizophrenia), tobacco and cannabis use, and social (e.g., 415 
socio-economic deprivation) and behavioral (e.g., educational attainment) outcomes. 416 
Analyses also revealed a genetic distinction between GWAS results for alcohol 417 
consumption and AD. Although larger sample sizes can be amassed by focusing on 418 
quantitative measures of consumption, only the upper tail is relevant to AD (as a 419 
medical diagnosis) and even that does not capture other aspects of disordered drinking 420 
(e.g., loss of control, withdrawal) directly. Conversely, cases derived from electronic 421 
medical records (e.g., ICD codes) result in a high rate of false negatives, while self-422 
screening instruments (e.g. AUDIT scores) are best suited to analyses of disordered 423 
drinking when a sufficiently high threshold or score cut-off is applied to focus on 424 
severity. Our study has the advantage of greater diagnostic precision via use of semi-425 
structured interviews to diagnose AD systematically in a majority of the constituent 426 
studies, and therefore greater interpretability in the context of clinically-important AD.  427 
 428 
The genome-wide significant SNPs reaffirm the importance of functional variants 429 
affecting alcohol metabolism to the risk of AD. The top association in ADH1B, 430 
rs1229984, is a missense variant that is amongst the most widely studied in relation to 431 
alcohol use, misuse and dependence8–10. The resulting amino acid substitution 432 
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(Arg48His) increases the rate at which alcohol dehydrogenase 1B oxidizes ethanol to 433 
acetaldehyde8. Studies on Asian populations in which the derived allele is common 434 
demonstrated strong protection against the development of AD8,9,13. In EU and AA, the 435 
protective allele is present at much lower frequencies (EU MAF = 0-4%, AA MAF < 1%), 436 
nevertheless, recent large-scale studies have shown an association between this locus 437 
and alcohol consumption and problems at GWS levels in EU with similar effect size8–10. 438 
The lead variant in AA cohorts, rs2066702 (Arg370Cys), is another functional missense 439 
variant in ADH1B, and it also encodes an enzyme with an increased rate of ethanol 440 
oxidation8. The allele encoding Cys370 is common in AA, but rare in other populations8. 441 
Our results clearly show that these two different functional SNPs in ADH1B both affect 442 
risk for alcoholism, with their relative importance dependent upon allele frequency in the 443 
population studied. There is a suggestion of additional independent effects in the 444 
chromosome 4 region, but larger studies will be needed to evaluate this. 445 
 446 
The only other locus to reach significance was rs7644567 on chromosome 3, primarily 447 
driven by AA cohorts. The locus failed to replicate in two small, independent AA 448 
samples, and in the only European cohort with even a modest allele frequency 449 
(FINRISK) the effect was in the opposite direction. There have also been discussions 450 
about whether the standard GWAS significance threshold should be applied to the more 451 
genetically diverse African-ancestry cohorts22,23 and the possibility of confounding from 452 
non-linear relationships between the phenotype and ancestry-informative markers like 453 
rs7644567 in admixed samples24, all of which increase our skepticism regarding this 454 
finding. There is, therefore, insufficient evidence at this time to conclude that rs7644567 455 
is associated with alcohol dependence. Analyses of much larger samples of African 456 
ancestry will be needed to resolve this. 457 
 458 
Despite limited SNP-level findings, there is significant evidence for polygenic effects of 459 
common variants in both EU and AA cohorts. The estimated h2g = 0.09 for AD in EU is 460 
only modestly lower than those recently reported for alcohol consumption (h2g = 0.13)17 461 
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and AUDIT scores (h2g = 0.12)18, and comparable to estimates derived for cigarettes-462 
per-day25. Our h2g estimate is lower than a prior report7, likely reflecting a combination of 463 
differences in estimation method (GREML vs. LDSR) and greater heterogeneity in 464 
ascertainment strategy across samples in the current study (see26–28). The latter is 465 
especially relevant in comparing h2g from that prior single cohort to our meta-analysis 466 
that included cohorts with a wide range of ages at ascertainment, cultural environments, 467 
and ascertainment strategies, including enrichment for other substance use disorders. 468 
Similar to other psychiatric disorders (e.g. schizophrenia), a much larger sample size 469 
will potentially aid in overcoming across-sample heterogeneity and capture a greater 470 
proportion of genetic variance.  471 
 472 
Comparing our GWAS to recent GWAS of alcohol consumption measures suggests that 473 
the liability underlying normative patterns of alcohol intake and AD are only partially 474 
overlapping. Genome-wide, genetic correlations were significantly < 1 with log-scaled 475 
alcohol consumption by participants in AlcGen and CHARGE+ Consortia cohorts16 (rg = 476 
0.695) and in the UK Biobank17 (rg = 0.371). We also observe only partial replication of 477 
the 8 loci significantly associated with consumption in the UK Biobank, with strongest 478 
results from SNPs in the ADH region, including a proxy for rs1229984. In addition there 479 
was no significant correlation with GWAS of log-scaled AUDIT scores in 23andMe 480 
participants18 (rg = 0.076). Subsequent analyses suggest these estimates are sensitive 481 
to sample characteristics, with somewhat higher genetic correlations reported in 482 
analysis of alcohol consumption in the full UK Biobank29 (rg = 0.75) and of AUDIT in 483 
combined data from 23andMe participants and UK Biobank30 (rg = 0.39). Importantly, 484 
initial UK Biobank data inclusion of a subset of participants recruited for a study of 485 
smoking and lung function in the first analysis17, which may have resulted in collider 486 
bias31 and contributed to the initial lower genetic correlation.  487 
 488 
One key factor in interpreting the differences between these traits and AD is that the 489 
distribution of consumption levels and AUDIT scores can be highly skewed in population 490 
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samples, with most individuals at the low (non-pathological) end of the spectrum. This 491 
effect may be especially pronounced among the older, healthy volunteers of the UK 492 
Biobank cohort32 and in the 23andMe cohort, which is more educated and has higher 493 
socioeconomic status than the general US population18. We hypothesize that the 494 
variants that affect consumption at lower levels may differ substantively from those that 495 
affect very high levels of consumption in alcohol dependent individuals, who are also 496 
characterized by loss of control over intake33. This appears to be the case in studies 497 
that used specific cut-offs to harmonize AUDIT scores with AD data30,34. The larger of 498 
these studies30 reports that the genetic correlation between AD and AUDIT scores is 499 
maximized at an AUDIT cutoff ≥ 20 (with controls defined as those scoring ≤ 4; rg = 500 
0.90). Interestingly, that study also found that a score reflecting items related to problem 501 
drinking (AUDIT-P) resulted in a stronger genetic correlation (rg = 0.64) than a score 502 
related to alcohol consumption alone (rg = 0.33). The strong genetic correlation of AD 503 
with lower educational attainment and lower socio-economic status (i.e. higher 504 
Townsend deprivation), in contrast to positive genetic correlations of education with 505 
consumption17 and AUDIT scores related to consumption30, further underscore this 506 
distinction between normative/habitual levels of alcohol intake and diagnosed AD, at 507 
least in the respective populations studied.  508 
 509 
The current analysis identified robust genetic correlation of AD with a broad variety of 510 
psychiatric outcomes. This correlation is strongest for aspects of negative mood, 511 
including neuroticism and major depression, as also seen in twin studies35,36 and 512 
through recent specific molecular evidence for pleiotropy37,38. Taken together with 513 
evidence from other recent genomic studies37, and null correlations for other GWAS of 514 
alcohol consumption, but not for measures of problem drinking (e.g., AUDIT-P), these 515 
findings suggest that major depression may primarily share genetic liability with alcohol 516 
use at pathological levels.  517 
 518 
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AD was also strongly genetically correlated with poor educational and socioeconomic 519 
outcomes, and marginally correlated with measures of risk-taking. Nominally significant 520 
genetic correlations with delay discounting (i.e. favoring immediate rewards), risk-taking, 521 
and the strong genetic correlation of AD with ADHD, cigarette smoking and cannabis 522 
use may similarly reflect a shared genetic factor for risk-taking and reduced impulse 523 
control. Common genetic liability to early, risky behaviors is characteristic of both AD39 524 
and age of first birth40. The observed negative genetic correlation with age of first birth is 525 
consistent both with risk-taking and with the significant genetic correlations of AD with 526 
lower socioeconomic status, as indexed by higher neighborhood Townsend deprivation 527 
score, and lower educational attainment. Lower socioeconomic status is correlated with 528 
both AD41 and age at first birth42 and the current study suggests that shared genetic 529 
liabilities may be one potential mechanism for their observed relationship. However, the 530 
question of whether these genetic correlations represent causal processes, horizontal 531 
pleiotropy, or the impact of unmeasured confounders should be explored in the future43. 532 
 533 
Lower genetic correlations were observed for most biomedical and anthropometric 534 
outcomes. Liver enzymes GGT and ALT, once proposed as possible biomarkers for 535 
alcohol abuse44, showed only nominal evidence for genetic correlation with AD and 536 
neither survived multiple testing correction. Notably, we did not find any association 537 
between AD and body-mass index (BMI). Negative genetic correlations with BMI were 538 
previously reported for both alcohol consumption17 and AUDIT scores18, but there is 539 
prior evidence that BMI has differing underlying genetic architecture in the context of AD 540 
and outside of that context45. The negative genetic correlations observed in those 541 
studies are consistent with studies of light to moderate drinking, which is also 542 
associated with healthier lifestyle behaviors, while heavy and problematic drinking is 543 
typically associated with weight gain46. 544 
 545 
This study benefits from precision in diagnostic assessment of AD, known alcohol 546 
exposure in a majority of the controls, and careful quality control that excluded overlap 547 
Walters, PGC-Alcdep 20 
 
of individuals between studies. Despite these strengths, our sample size was insufficient 548 
to identify additional GWS loci robustly. Power analyses indicate that additional SNPs 549 
associated with AD are likely to have small effect sizes, smaller than schizophrenia47 550 
and more consistent with more common psychiatric disorders (e.g. major depression48). 551 
This supports the pressing need for collection of large numbers of well characterized 552 
cases and controls. The differences between our results and the study of AUDIT 553 
scores18 highlight that ascertainment and trait definition are critically important and must 554 
be taken into account. Careful study of how screening tools, such as the AUDIT, 555 
correlate to genetic liability to AD (as defined by DSM-IV or similar) could substantially 556 
boost sample sizes for future AD GWAS. There is also a continued need to characterize 557 
the genetic architecture of AD in non-EU populations.  558 
 559 
We show a novel genetic distinction between drinking in the pathological range (AD) 560 
and habitual drinking that does not cross the threshold into pathology or dependence 561 
nor captures behavioral aspects of disordered drinking. Larger future samples will allow 562 
us to uncover additional pleiotropy between pathological and non-pathological alcohol 563 
use as well as between AD and other neuropsychiatric disorders.  564 
  565 
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Figure Legends 1112 
Figure 1: Manhattan plot of discovery trans-ancestral meta-analysis showing 1113 
strong evidence for rs1229984 in ADH1B. 1114 
Results from the discovery meta-analysis of all cohorts (Ncase=14,904, Ncontrol=37,944) 1115 
for association of genome-wide SNPs with AD under a fixed effects meta-analysis 1116 
weighted by effective sample size. Dashed red reference line indicates genome-wide 1117 
significance after correction for multiple testing (p < 5E-8).  1118 
 1119 
Figure 2: Regional plots for the ADH1B locus (rs1229984) in the trans-ancestral 1120 
discovery, African-American (AA), and European (EU), meta-analyses. 1121 
Results of fixed effects meta-analysis with effective sample size weights for the ADH1B 1122 
locus in (A) all cohorts (Ncase=14,904, Ncontrol=37,944); (B) AA cohorts (Ncase=3,335, 1123 
Ncontrol=2,945); and (C) EU cohorts (Ncase=11,569, Ncontrol=34,999). Red reference line 1124 
indicates the genome-wide significance threshold after correction for multiple testing 1125 
within each analysis (p < 5E-8). Within ancestry, colored points reflect the degree of LD 1126 
(pairwise r2) to the index variant (indicated by a purple diamond) in 1000 Genomes 1127 
Project reference data21 for individuals of (B) African or (C) European ancestry, 1128 
respectively. LD structures in the two ancestries differ, so for the trans-ancestral sample 1129 
(A) LD is not given, indicted by gray points. Two-tailed tests used for all analyses. 1130 
 1131 
Figure 3: Genetic correlations between 45 traits and alcohol dependence in 1132 
Europeans. 1133 
Genetic correlation results from LD score regression (LDSR) with the meta-analysis of 1134 
AD in unrelated EU individuals (Ncase=10,206, Ncontrol=28,480). After Bonferroni 1135 
correction, significant correlations are observed with 17 traits and disorders (p < 1.1E-3; 1136 
bold), with nominally significant results for 8 additional traits and disorders (p < .05; 1137 
italics) based on two-tailed tests of the estimated genetic correlation with block jackknife 1138 
standard errors. Error bars indicate 95% confidence intervals, with arrows indicating 1139 
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intervals extending above 1 or below -1. Vertical gray reference line corresponds to the 1140 
null hypothesis of no genetic correlation with AD. Phenotypes are organized by 1141 
research domain. 1142 
  1143 
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TABLES 
Table 1: Descriptive statistics for cohorts in the meta-analysis of AD. 
  
European (EU) African - American (AA)   
Male Ages N Total N Unrelated N Total N Unrelated 
Dataset PMID (%) (years) Case Control Case Control Case Control Case Control 
Case-control: Logistic Regression                       
Comorbidity and Trauma Study (CATS) 23303482 56% 18-67  572 817 572  817  -- -- -- -- 
Christchurch Health and Development Study (CHDS) 23255320 48% 16-30 112 500 112  500  -- -- -- -- 
Collaborative Study of the Genetics of Alcoholism - case-control cohort (COGA-cc) 20201924 54% 18-79 583 363 583  363  -- -- -- -- 
Family Study of Cocaine Dependence (FSCD) 18243582 51% 18-60 266 174 266  174  255 241 255  241  
German Study of the Genetics of Alcoholism (GESGA) 19581569 65% 18-84 1314 2142 1314  2142  -- -- -- -- 
Gene-Environment Development Initiative - Great Smoky Mountains Study (GEDI-GSMS) 8956679 57% 9-26 42 565 42  565  -- -- -- -- 
Center on Antisocial Drug Dependence (CADD) 25637581 70% 13-20 400 577 400  577  51 51 51  51  
Phenomics and Genomics Sample (PAGES) 28371232 57% 18-74 37 523 37  523  -- -- -- -- 
Collaborative Study on the Genetics of Nicotine Dependence (COGEND Nico) 17158188 34% 25-82 135 272 135  272  46 232 46  232  
COGEND - Study of Addiction: Genetics and Environment (COGEND SAGE) 20202923 37% 18-77 311 225 311  225  104 103 104  103  
Spit For Science 24639683 36% >18 252 1863 252  1863  74 841 74  841  
National Institute on Alcohol Abuse and Alcoholism Intramural (NIAAA) n/a 67% >18 442 206 442  206  404 110 404  110  
Mayo Clinic Center for the Individual Treatment of Alcohol Dependence (CITA) 25290263 55% ≥18 378 646 378  646  -- -- -- -- 
Alcohol Dependence in African Americans (ADAA) n/a 57% 18-69 -- -- -- -- 794 297 794  297  
Family-based, twins and sibs: Generalized Estimating Equations (GEE)                       
Brisbane Longitudinal Twin Study (BLTS) 23187020 43% 18-30 60 938 51  546  -- -- -- -- 
GEDI - Virginia Twin Study on Adolescent Behavioral Development (GEDI-VTSABD) 9294370 38% 8-32 209 503 188  318  -- -- -- -- 
Minnesota Center for Twin and Family Research (MCTFR) 23942779 41% 16-21 609 2100 553  1274  -- -- -- -- 
Center for Education and Drug Abuse Research (CEDAR) 21514569 63% 16-34 59 200 54  152  -- -- -- -- 
Swedish Twin Registry (STR) 23137839 47% 40-83 76 8311 76  6112  -- -- -- -- 
Yale-Penn 24166409 58% 16-79 1094 301 1004  252  -- -- -- -- 
Family-based, large/complex pedigrees: Logistic Mixed Model                       
Collaborative Study of the Genetics of Alcoholism - family cohort (COGA-fam) 23089632 45% 12-88 605 682 168  138  -- -- -- -- 
Australian Alcohol and Nicotine Studies (OZ-ALC-NAG) 21529783 45% 18-82 1571 3069 1111  805  -- -- -- -- 
Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD) 15770118 50% 17-84 721 1814 436  1802  -- -- -- -- 
Yale-Penn 24166409 51% 16-79 -- -- -- -- 1607 1070 1263  933  
Summary statistics                       
Netherlands Study of Depression and Anxiety / Netherlands Twin Registry (NESDA/NTR) 18197199 31% >18 390 1633 390 1633 -- -- -- -- 
Finnish Nicotine Addiction Genetics Project (NAG-Fin) 17436240 52% 30-92 439 1137 439 1137 -- -- -- -- 
FinnTwin12 (FT12) 17254406 47% 20-27 88 874 88 874 -- -- -- -- 
National Longitudinal Study of Adolescent to Adult Health (Add Health) 25378290 47% 24-34 768 2981 768 2981 -- -- -- -- 
Helsinki Birth Cohort Study (HBCS) 16251536 43% 56-70 36 1583 36  1583  -- -- -- -- 
Total    11569 34999 10206 28480 3335 2945 2991 2808 
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Overview of numbers of alcohol dependent cases and controls from each cohort in the current analysis, including the number of 
genetically unrelated individuals. Cohorts are listed by study design and analysis method. Sample sizes are listed after QC exclusions 
and stratified by ancestry group. PubMed identifiers (PMID) are listed for previous publications describing each cohort, along with the 
percentage of male samples and the age range in the cohort.  
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Table 2: Top 10 loci from the meta-analyses of alcohol dependence by ancestry 
      
A1 Allele Freq. INFO score Effect size (OR) Discovery meta-analysis p-value 
SNP CHR BP A1 A2 Gene EU AA EU AA EU AA EU AA Trans 
Top clumped variants in trans-ancestral meta-analysis (14,904 cases, 37,944 controls) 
rs7644567* 3 29201672 A G RBMS3 0.964 0.705 0.96 1.00 -- 1.229 3.94E-04 6.64E-06 1.36E-08 
rs2066702 4 100229017 A G ADH1B -- 0.215 -- 0.99 -- 0.731 -- 2.21E-09 2.21E-09 
rs1229984 4 100239319 T C ADH1B 0.040 0.014 0.90 0.91 0.486 0.912 9.79E-13 3.48E-01 2.18E-11 
rs1789912 4 100263942 T C ADH1C 0.418 0.132 1.00 1.02 1.106 1.211 1.98E-07 1.32E-03 1.47E-09 
rs6827898 4 100295863 A G (ADH region) 0.123 0.112 0.96 0.94 1.145 1.270 5.21E-07 9.31E-04 2.97E-09 
rs894368 4 100309313 A C (ADH region) 0.309 0.386 0.99 0.96 0.887 0.981 1.93E-08 9.73E-01 3.30E-07 
rs2461618 7 68667233 A G -- -- 0.088 -- 0.98 -- 0.669 -- 6.30E-07 6.30E-07 
rs116338421 8 145761256 C G ARHGAP39 -- 0.172 -- 0.97 -- 0.755 -- 4.86E-07 4.86E-07 
rs79171978 12 17798824 C G -- 0.099 0.027 0.99 0.99 1.201 1.016 5.47E-08 8.18E-01 5.98E-07 
rs8017647 14 32456358 T C -- 0.792 0.565 1.00 0.99 0.901 0.923 8.05E-06 4.71E-02 1.03E-06 
Top clumped variants in African ancestry meta-analysis (3,335 cases, 2,945 controls) 
rs5781337 1 223883425 CA C -- 0.263 0.212 0.98 0.93 1.007 0.664 8.85E-01 1.62E-07 6.59E-02 
rs143258048 3 75982870 A AC ROBO2 -- 0.028 -- 0.88 -- 0.490 -- 1.86E-06 -- 
rs3857224 4 100129685 T C ADH6 0.315 0.585 0.99 1.00 0.970 0.814 2.40E-01 5.86E-07 2.36E-03 
rs2066702 4 100229017 A G ADH1B -- 0.215 -- 0.99 -- 0.731 -- 2.21E-09 2.21E-09 
rs2461618 7 68667233 A G -- -- 0.088 -- 0.98 -- 0.669 -- 6.30E-07 6.30E-07 
rs116338421 8 145761256 C G ARHGAP39 -- 0.172 -- 0.97 -- 0.755 -- 4.86E-07 4.86E-07 
rs79016499 11 93010988 T C -- -- 0.066 -- 0.93 -- 1.729 -- 1.36E-06 -- 
rs10784244 12 62035165 G A -- 0.153 0.484 1.00 1.00 1.041 1.226 6.26E-02 1.04E-06 2.49E-04 
rs17199739 16 25444288 G A -- 0.176 0.096 0.99 0.96 0.994 0.693 4.25E-01 1.11E-06 8.66E-03 
rs740793 17 3846353 G A ATP2A3 0.453 0.350 0.97 0.97 0.996 1.370 4.66E-01 1.48E-06 3.44E-01 
Top clumped variants in European ancestry meta-analysis (11,569 cases, 34,999 controls) 
rs1229984 4 100239319 T C ADH1B 0.040 0.014 0.90 0.91 0.486 0.912 9.79E-13 3.48E-01 2.18E-11 
rs3811802 4 100244221 G A ADH1B 0.454 0.529 0.96 0.96 1.162 0.914 2.40E-08 2.19E-02 1.22E-04 
rs113659074 4 100252308 T G ADH1B 0.068 0.093 0.98 0.95 0.800 1.166 1.54E-06 6.63E-02 2.99E-04 
rs1229863 4 100252386 A T ADH1B 0.174 0.038 0.99 0.99 1.145 1.254 7.80E-07 4.26E-02 9.28E-08 
rs1154445 4 100288521 G T (ADH region) 0.425 0.134 0.97 0.99 1.137 1.211 1.80E-07 2.63E-02 1.48E-08 
rs6827898 4 100295863 A G (ADH region) 0.123 0.112 0.96 0.94 1.145 1.270 5.21E-07 9.31E-04 2.97E-09 
rs894368 4 100309313 A C (ADH region) 0.309 0.386 0.99 0.96 0.887 0.981 1.93E-08 9.73E-01 3.30E-07 
rs79171978 12 17798824 C G -- 0.099 0.027 0.99 0.99 1.201 1.016 5.47E-08 8.18E-01 5.98E-07 
rs4388946 12 17935154 C A -- 0.240 0.297 0.99 0.98 1.137 0.950 7.14E-07 1.87E-01 7.05E-05 
rs34929220 15 69769635 T C DRAIC 0.690 0.937 0.90 0.94 0.893 1.028 1.02E-06 8.38E-01 7.38E-06 
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Top 10 nominally independent variants from the discovery trans-ancestral (Trans.; Ncase=14,904, Ncontrol=37,944) meta-analysis and the 
discovery meta-analyses in African (AA; Ncase=3,335, Ncontrol=2,945) and European (EU; Ncase=11,569, Ncontrol=34,999) ancestry cohorts, 
respectively. Independent variants are identified based on clumping for LD (pairwise r2 < 0.1) in 1000 Genomes Project Phase 3 data21. 
EU results are clumped using European (EUR) ancestry reference samples, AA results are clumped using African ancestry reference 
samples from the American Southwest (ASW), and trans-ancestral results are clumped using merged EUR and African ancestry (AFR) 
reference samples.  P-values and allele frequencies (Freq.) are reported from two-tailed tests of association with AD in fixed effects 
meta-analyses weighted by effective sample size. Bold p-values indicate genome-wide significance after correction for multiple testing 
within the analysis (p < 5E-8). Odds ratios (OR) and INFO scores are reported from the meta-analyses of the subset of unrelated 
individuals within each ancestry. Variants are sorted by chromosome (CHR) and base pair (BP) position for genome build hg19, with 
genes annotated by Ensembl VEP49. Allele frequency and OR are given with respect to allele 1 (A1). 
SNPs included in the trans-ancestral meta-analysis were not conditioned on being analyzed in both the EU and AA analyses. For 
instance, a SNP of strong effect in one group may not be sufficiently common or well-imputed for analysis in the other ancestral group 
(e.g., rs2066702 is not found in non-African populations but is among the top 10 in the trans-ancestral analysis due to strong effects in 
the AA group). For rs7644567 (denoted with *), the SNP does not passed QC in a sufficient number of cohorts to meet the minimum 
sample size requirement for inclusion in the EU-only analyses – it is only represented among EU cohorts by summary statistics from 
two Finnish cohorts – but allele frequency, INFO score, and meta-analyzed p-values from the Finnish summary statistics are reported 
since they contribute to the trans-ancestral meta-analysis.
Walters, PGC-Alcdep 41 
 
 
METHODS 
 
Samples: The Substance Use Disorders working group of the Psychiatric Genomics 
Consortium (PGC-SUD14) collected individual genotypic data from 14 case/control 
studies and 9 family-based studies and summary statistics from GWAS of AD from 5 
additional cohorts (Table 1). AD was defined as meeting criteria for a DSM-IV2 (or, for 
one cohort, DSM-IIIR50; a very similar construct; Supplementary Note B1) diagnosis of 
AD. Diagnoses were derived either from clinician ratings or semi-structured interviews. 
Excepting three cohorts with population-based controls (N=7,015), all controls were 
screened for AD. Individuals with no history of drinking alcohol and those meeting 
criteria for DSM-IV alcohol abuse were excluded as controls where possible 
(Supplementary Information A1; Life Sciences Reporting Summary). This study 
was approved by the institutional review board (IRB) of Washington University in St. 
Louis and was conducted in accordance with all relevant ethical regulations. Each 
contributing cohort obtained informed consent from their participants and received 
ethics approvals of their study protocols from their respective review boards in 
accordance with applicable regulations.  
 
Quality Control and Imputation: Data for the cohorts that shared raw genotypes were 
deposited to a secure server for uniform quality control (QC). QC and imputation of the 
14 case/control studies was performed using the ricopili pipeline 
(https://github.com/Nealelab/ricopili). For the 9 family-based cohorts, an equivalent 
pipeline, picopili (https://github.com/Nealelab/picopili), was developed for QC, 
imputation, and analysis appropriate for diverse family structures, including twins, 
sibships and extended pedigrees (Supplementary Information A2). 
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After initial sample and variant QC, principal components analysis (PCA) was used to 
identify population outliers for exclusion and to stratify samples in each study by 
continental ancestry. Identified EU and AA ancestry populations were confirmed by PCA 
using the 1000 Genomes reference panel21 (Supplementary Figure S12). Ancestry 
within these 2 groups was accounted for with principal components. Final sample and 
variant QC, including filters for call rate, heterozygosity, and departure from Hardy-
Weinberg equilibrium (HWE), was then performed within each ancestry group in each 
cohort. Samples were also filtered for cryptic relatedness and for departures from 
reported pedigree structures (Supplementary Information A3; Life Sciences 
Reporting Summary).  
 
Each cohort was imputed using SHAPEIT51 and IMPUTE252, using the cosmopolitan (all 
ancestries) 1000 Genomes reference panel consistent with prior recommendations53 
(see also47,54,55). Concordance of minor allele frequencies (MAF) with the reference 
panel was verified prior to imputation, with SNPs in EU cohorts compared to MAF in 
European population samples and AA cohorts compared to MAF in African population 
samples (Supplementary Information A4). Cryptic relatedness between cohorts was 
excluded after imputation (Supplementary Information A5). Imputed SNPs were then 
filtered for INFO score > 0.8 and allele frequency > 0.01 prior to analysis. 
 
Association Analysis: A GWAS of AD status was performed within each ancestry 
stratum of each sample using an association model appropriate for the study design 
(Table 1, Supplementary Table S1). For case/control studies, GWAS was performed 
using logistic regression with imputed dosages. For family-based studies of small, 
simple pedigrees (e.g., sibships), association with imputed genotypes was tested using 
generalized estimating equations (GEE). For more complex pedigrees, imputed 
genotypes were tested using logistic mixed models. Sex was included as a covariate, 
along with principal components to control for population structure (Supplementary 
Information A6, Supplementary Note B2, Supplementary Figures S13-S14).  
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In addition to this primary analysis, subsets of genetically unrelated individuals were 
selected from each family-based cohort (i.e. the most severe case in each family, by 
symptom count, was selected, followed by selection of unrelated/married-in controls) 
and used to perform a conventional case/control GWAS using logistic regression. This 
was used in place of the family-based GWAS for estimation of effect sizes and LD score 
regression analyses (Supplementary Table S2).  
 
Genome-wide Meta-Analysis: The primary discovery meta-analysis of all ancestry-
stratified GWAS (Ncase = 14,904; Ncontrol = 37,944) was conducted in METAL56. As the 
different study designs (family vs. case-control) produced effect sizes that were not 
comparable, results were combined using weighting by effective sample size 
(Supplementary Information A7, Supplementary Note B3). Separate ancestry-
specific discovery meta-analyses of EU (N = 46,568) and AA (N = 6,280) cohorts were 
also performed. Heterogeneity was evaluated across all cohorts and between study 
designs (Supplementary Information A8).  
 
In addition to the discovery meta-analyses, we conducted meta-analyses for two design 
subsets. First, we performed sample size weighted meta-analysis of the subset of 
genetically unrelated individuals in EU (N = 38,686) and AA (N = 5,799) cohorts for use 
in LD score regression (LDSR) analysis. Second, we performed inverse-variance 
weighted meta-analysis of genetically unrelated individuals in genotyped cohorts to 
estimate within-ancestry effect sizes for EU (N = 28,757) and AA (N = 5,799). These 
effect sizes were then used to compare trans-ancestral fine mapping results using 
inverse-variance weighted fixed effects, random effects57, and Bayesian58 models 
(Supplementary Information A7). Supplementary Table S2 summarizes all of the 
meta-analytic models considered in the current analysis. 
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Replication: As described below, a novel locus on chromosome 3 was genome-wide 
significant (GWS) in the trans-ancestral discovery meta-analysis. To seek replication, 
we examined the association between this locus and DSM-IV AD in two independent 
AA samples: Yale-Penn 2 (911 cases, 599 controls; tested using GEE) and COGA 
AAfGWAS (880 cases, 1,814 controls; tested using GWAF59). Association with AD 
status, broadly defined using hospital and death records, was also examined in the 
FINRISK cohort (1,232 cases, 22,614 controls) using Firth logistic regression60 
(Supplementary Information A1.4; Life Sciences Reporting Summary). 
 
Power Analysis: Post-hoc power analysis was performed for odds ratios ranging from 
1.05 to 1.30 and across allele frequencies using CaTS61 with the estimated effective 
sample size. Power analysis identifies the range of SNP effect sizes the current study 
was likely to detected at genome-wide significance if such effects exist. Additionally, we 
made specific comparisons to the distribution of effects for schizophrenia47, obesity62 
and major depression48 as meaningful benchmarks to understand the magnitude of 
effect sizes plausible for AD (Supplementary Information A10; Life Sciences 
Reporting Summary). 
 
Heritability and Genetic Correlation Analysis: LDSR analysis63 was performed to 
estimate the heritability explained by common SNPs in meta-analyses of unrelated EU 
and AA samples, respectively. LDSR was performed using HapMap3 SNPs and LD 
scores computed from 1000 Genomes reference samples corresponding to each 
population (Supplementary Information A11). Conversion of h2g estimates from 
observed to liability scale64 was performed assuming population prevalences of 0.159 
and 0.111 for AD in alcohol-exposed EU and AA individuals, respectively3. Gene-level 
enrichments were also tested with MAGMA15 (Supplementary Information A12). 
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Genetic correlation between AD and 45 traits from LD Hub25 and other published 
studies16–19,65–71 was examined using LDSR with the same unrelated EU meta-analysis 
(10,206 cases and 28,480 controls) and precomputed European LD scores. LDSR 
compares GWAS results for pairs of traits to estimate the correlation in the genetic 
liabilities explained by all common SNPs in the LD reference panel. To avoid increasing 
the multiple testing burden, redundant or highly-correlated phenotypes were reduced by 
manually selecting the version of the phenotype with the greatest predicted relevance to 
AD, largest sample size, or highest heritability (Supplementary Information A13). 
 
Polygenic Risk Scores: To test the generalizability of the current GWAS results, 
polygenic risk scores (PRS) were computed in three external cohorts (Supplementary 
Information A1.5; Life Sciences Reporting Summary). PRS computed from EU 
ancestry results were used to predict alcohol dependence in ALSPAC72,73 and COGA 
AAfGWAS, and CAGE screener scores in Generation Scotland (GS)74. PRS based 
upon the AA results were used to predict alcohol dependence in COGA AAfGWAS 
(Supplementary Information A14).  
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Data availability: 
Summary statistics from the genome-wide meta-analyses are available on the 
Psychiatric Genomics Consortium’s downloads page 
(http://www.med.unc.edu/pgc/results-and-downloads), including the source data for 
Figures 1 and 2. Individual-level data from the genotyped cohorts and cohort-level 
summary statistics will be made available to researchers following an approved analysis 
proposal through the PGC Substance Use Disorder group with agreement of the cohort 
PIs; contact the corresponding authors for details. Cohort data are also available from 
dbGaP except where prohibited by IRB or European Union data restrictions. Expression 
data used to evaluate variants in ADH1B is available from GTEx 
(https://gtexportal.org/home/). Hi-C data used to evaluate the chromosome 3 variant can 
be queried with HUGIn (https://yunliweb.its.unc.edu/hugin/). Publicly available genome-
wide summary statistics used for testing genetic correlations are accessible through LD 
Hub (http://ldsc.broadinstitute.org/), or from the Psychiatric Genomics Consortium 
(http://www.med.unc.edu/pgc/results-and-downloads), the Social Science Genetic 
Association Consortium (SSGAC; https://www.thessgac.org/data), Enhancing Neuro 
Imaging Genetics through Meta Analysis (ENIGMA; 
http://enigma.ini.usc.edu/research/download-enigma-gwas-results/), and the Neale Lab 
(http://www.nealelab.is/uk-biobank); for availability of summary statistics from other 
studies contact the respective authors. The source data for Figure 3 is included in 
Supplementary Table S6. 
 
Code availability: 
Code for GWAS of case/control cohorts with ricopili is available at https://github.com/
Nealelab/ricopili. Code for GWAS of family-based cohorts with picopili is available at 
https://github.com/Nealelab/picopili. Code and reference data for LD score regression 
analyses are available at https://github.com/bulik/ldsc. Effective sample size 
calculations were implemented using output from PLINK (https://www.cog-
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genomics.org/plink2), and GMMAT 
(https://content.sph.harvard.edu/xlin/software.html#gmmat) and geepack (https://cran.r-
project.org/web/packages/geepack/index.html) in R (https://cran.r-project.org/); stand-
alone software for this purpose hasn’t been written but example code is available from 
the first author by request.  
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